Premium Insights - Medical Imaging

Read our Analysts’ insights and expert opinions on the latest healthcare technology industry developments and market trends. Signify Research provides both free insights and premium insights which are only available to subscribers of "Signify Premium Insights".
Click on the premium insights link below to filter for just the premium content.



Signify Premium Insight: Perspectum’s Persuasive Value Proposition

Signify Premium Insights – Medical Imaging Subscription Required

February 2nd 2023 – Perspectum has recently secured $36m in Series C funding. It is a figure that, compared to its peers, is surprisingly low, particularly given Perspectum’s credentials. Is there a reason for this financial modesty?

Signify Premium Insight: In Contrast to Convention, Guerbet Bets on Intrasense

Signify Premium Insights – Medical Imaging Subscription Required

January 31st 2023 – Guerbet has upped its focus on AI with an investment in French vendor Intrasense. Not only does this add options for providers looking for an AI platform, it also raises possibilities in AV.

Signify Premium Insight: Bayer Acquires Blackford as Platforms Become Priority

Signify Premium Insights – Medical Imaging Subscription Required

January 26th 2023 – Bayer announced it is acquiring AI platform provider Blackford Analysis. Bayer says it will allow Blackford to continue to operate independently, but, is this really the best option?

Signify Premium Insight: Teleradiology’s Compensation Calculation

Signify Premium Insights – Medical Imaging Subscription Required

January 24th 2023 – Teleradiology’s fortunes are inexorably linked to those of the wider medical imaging market. However, as Senior Market Analyst, Arun Gill, explains, there are also some more nuanced trends that are shaping the market.

Signify Premium Insight: The Right Path for Fujifilm

Signify Premium Insights – Medical Imaging Subscription Required

January 19th 2023 – Fujifilm has taken its partnership with Inspirata a step further, acquiring the vendor’s digital pathology business. It’s a sensible step, but what broader benefits is it also likely to bring?